Patents Examined by Garnette Draper
  • Patent number: 4952394
    Abstract: There is disclosed a drug-monoclonal antibody conjugate wherein the antibody is linked to a antitumor drug using disulfide benzyl carbamate or carbonate as the linker. Also disclosed is a method of delivering an active antitumor drug to the site of tumor cells in a mammal by administering the drug-monoclonal antibody conjugate.
    Type: Grant
    Filed: November 23, 1987
    Date of Patent: August 28, 1990
    Assignee: Bristol-Myers Company
    Inventor: Peter D. Senter
  • Patent number: 4952404
    Abstract: Healing of injured avascular tissue is promoted by applying angiogenic factor in proximity to the injured tissue.
    Type: Grant
    Filed: June 19, 1987
    Date of Patent: August 28, 1990
    Assignee: President and Fellows of Harvard College
    Inventors: Bert L. Vallee, Thomas V. King
  • Patent number: 4952676
    Abstract: A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilizes the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.
    Type: Grant
    Filed: July 20, 1988
    Date of Patent: August 28, 1990
    Assignee: Johnson Matthey PLC
    Inventors: James G. Heffernan, Michael J. Cleare, Donald H. Picker
  • Patent number: 4950480
    Abstract: A new method is described for eliciting IgG antibody response to proteins or synthetic peptides without the requirement for the use of adjuvants, thereby making it easier and safer to confer protection against pathogenic organisms. The antigen is coupled to a monoclonal antibody, specific for membrane determinants expressed on certain types of mammalian recipient cells, called antigen presenting cells. The monoclonal antibody acts as a "vector" or "delivery vehicle" for targeting foreign antigens onto such recipient cells. This targeting facilitates subsequent antigen recognition by helper T-cells, which are pivotal in helping the induction of antigen-specific IgG responses.
    Type: Grant
    Filed: May 5, 1987
    Date of Patent: August 21, 1990
    Assignee: Connaught Laboratories Limited
    Inventors: Brian H. Barber, George Carayannotis
  • Patent number: 4946945
    Abstract: A protein conjugate or mixture useful in immunotherapy composed of a biological response modifier (BRM) and an allergen is disclosed. In use the protein conjugate or mixture is combined with a pharmaceutically acceptable carrier. Cytokines, bacterial, fungal and viral immunopotentiators and thymus hormones are disclosed as suitable BRM's for use in the invention.
    Type: Grant
    Filed: June 23, 1987
    Date of Patent: August 7, 1990
    Assignee: Allergy Immuno Technologies, Inc.
    Inventor: Aristo Wojdani
  • Patent number: 4946675
    Abstract: Novel methods and compositions are provided for the enhancement of the biodistribution of immunoconjugates useful in the diagnosis and treatment of a variety of conditions including cancer in many of its forms. The compositions of the present invention provide for enhanced bioavailability of immunoconjugates for the most part by blocking mammalian cell surface receptors present on cells of the reticuloendothelial system, especially in tissues responsible for the elimination of waste products and blood filtration. Such tissues include the liver, spleen, and kidneys. The compositions are administered in conjunction with an immunoconjugate in a pharmaceutically acceptable vehicle and may be provided in kits for convenient administration.
    Type: Grant
    Filed: May 27, 1987
    Date of Patent: August 7, 1990
    Assignee: Xoma Corporation
    Inventors: Robert W. Baldwin, Vera S. Byers
  • Patent number: 4938956
    Abstract: The known immunostimulants FK-565 and IL-2 are administered to animals in conjunction to synergistically stimulate the immune system.
    Type: Grant
    Filed: April 1, 1987
    Date of Patent: July 3, 1990
    Assignee: International Minerals & Chemical Corp.
    Inventors: David K. Howard, Ellen R. Clough, Anthony F. Abruzzini, Paula Myers-Keith
  • Patent number: 4935234
    Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: June 19, 1990
    Assignee: Dana-Farber Cancer Institute
    Inventors: Robert F. Todd, III, Paul J. Simpson, Benedict R. Lucchesi, Stuart F. Scholossman, James D. Griffin
  • Patent number: 4931547
    Abstract: Monoclonal antibodies demonstrating reactivity to genus-specific epitopes present on outer membrane proteins of bacteria of the genus Legionella and hybridomas for secreting the antibodies are disclosed.
    Type: Grant
    Filed: May 31, 1988
    Date of Patent: June 5, 1990
    Assignee: The University of Tennesse Research Corporation
    Inventors: Paul S. Hoffman, Leta O. Helsel, William F. Bibb, Roger M. McKinney
  • Patent number: 4755382
    Abstract: A method is disclosed for stimulating the immune system of a warm-blooded animal by the production of antibodies by administering an effective amount of Cytophaga allerginae lipopolysaccharide endotoxin.
    Type: Grant
    Filed: June 13, 1985
    Date of Patent: July 5, 1988
    Assignee: Monsanto Company
    Inventor: Dennis K. Flaherty
  • Patent number: 4690819
    Abstract: A method for stabilizing rubella HA antigen which comprises adjusting a rubella HA antigen suspension at pH 9.6 or higher, and more preferably, concurrently adding sodium azide thereto, or adding sodium azide alone at a concentration of 1 to 10% (w/v) thereto without the above adjustment of pH.
    Type: Grant
    Filed: October 28, 1985
    Date of Patent: September 1, 1987
    Assignee: Shionogi & Co., Ltd.
    Inventors: Akihiko Sato, Akira Noto, Fumiaki Morita, Kunihiro Nakajima